US20050037060A1 - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
US20050037060A1
US20050037060A1 US10/949,116 US94911604A US2005037060A1 US 20050037060 A1 US20050037060 A1 US 20050037060A1 US 94911604 A US94911604 A US 94911604A US 2005037060 A1 US2005037060 A1 US 2005037060A1
Authority
US
United States
Prior art keywords
pharmaceutical composition
weight
minoxidil
approximately
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/949,116
Inventor
Tony Wai-Chiu So
Peter Deo
Russell Tait
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Research Australia Pty Ltd
Original Assignee
Connetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3807366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20050037060(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Connetics Corp filed Critical Connetics Corp
Priority to US10/949,116 priority Critical patent/US20050037060A1/en
Publication of US20050037060A1 publication Critical patent/US20050037060A1/en
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT FIRST LIEN PATENT SECURITY AGREEMENT Assignors: CONNETICS CORPORATION, STIEFEL LABORATORIES, INC.
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT SECOND LIEN PATENT SECURITY AGREEMENT Assignors: CONNETICS CORPORATION, STIEFEL LABORATORIES, INC.
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT FIRST LIEN PATENT SECURITY AGREEMENT Assignors: CONNETICS CORPORATION, STIEFEL LABORATORIES, INC.
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERAL AGENT SECOND LIEN PATENT SECURITY AGREEMENT Assignors: CONNETICS CORPORATION, STIEFEL LABORATORIES, INC.
Assigned to STIEFEL RESEARCH AUSTRALIA PTY LTD reassignment STIEFEL RESEARCH AUSTRALIA PTY LTD CHANGE OF NAME Assignors: CONNETICS AUSTRALIA PTY LTD
Assigned to CONNETICS CORPORATION, STIEFEL LABORATORIES, INC. reassignment CONNETICS CORPORATION RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT Assignors: DEUTSCHE BANK TRUST COMPANY AMERICAS
Assigned to CONNETICS CORPORATION, STIEFEL LABORATORIES, INC. reassignment CONNETICS CORPORATION RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT Assignors: DEUTSCHE BANK TRUST COMPANY AMERICAS
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00Preparations for affecting hair growth

Definitions

  • the present invention relates to a vehicle system for a pharmaceutical composition comprising a piperidinopyrimidine derivative. More particularly minoxidil and to a pharmaceutical composition incorporating the vehicle system.
  • Minoxidil is a pharmaceutically active ingredient having several indications including use as a hair growth stimulant.
  • Minoxidil has poor solubility in water and ethanol and pharmaceutical preparations currently marketed only contain a small percentage of minoxidil. That is, below 5%.
  • the present invention in a first aspect provides a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
  • a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.
  • the solubility of the piperidinopyrimidine derivatives may be significantly increased without the necessity of utilising large amounts of propylene glycol or optionally by excluding propylene glycol altogether. Accordingly the total amount of active in the composition may be significantly increased.
  • the pharmaceutically active component is present in amounts of approximately 5 to 25% by weight, preferably approximately 5 to 15% by weight, more preferably approximately 7.5 to 12% by weight.
  • the piperidinopyrimidine derivative is minoxidil.
  • the minoxidil is present in the form of a salt.
  • the salt may include acetate, citrate, succinate, benzoate, hydrochloride, sulphate, phosphate or lactate.
  • an acetate or lactate salt of minoxidil is used.
  • the acetate or lactate salts may exhibit enhanced solubility and improve the ability to incorporate increased amounts of the active component in the composition.
  • the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.
  • the apparent pH of the composition is preferably between approximately 5.0 to 7.0, more preferably between 6.0 to 6.5.
  • Any suitable acid may be used to adjust the pH, including mineral acids, such as hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid, or organic acids such as citric acid, acetic acid, succinic acid, or maleic acid, or mixtures thereof.
  • Acetic acid or lactic acid is preferred.
  • the acid is present at a level that provides at least 0.01 Normal acid.
  • the acid is present in an amount equal to, or greater than, the amount of the piperidinopyrimidine derivative in Normal amounts.
  • the lower alcohol is ethanol.
  • the ratio of water to ethanol is preferably from approximately 9:1 to 1;9, more preferably approximately 1:1 to 1:3, by volume.
  • the co-solvent includes benzyl alcohol.
  • the benzyl alcohol may be present in amounts of approximately 2.5 to 95% by weight, preferably approximately 5 to 40% by weight, based on the total weight of the pharmaceutical composition.
  • the co-solvent may include a polyhydric alcohol, for example a polyol selected from the group consisting of 1,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol.
  • a polyhydric alcohol for example a polyol selected from the group consisting of 1,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol.
  • propylene glycol When propylene glycol is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight, or less.
  • compositions comprising 5% of minoxidil or greater, it is preferred to include benzyl alcohol in the composition.
  • the benzyl alcohol may be present in amounts of up to 85% by weight, based on the total weight of the pharmaceutical composition.
  • the co-solvent system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight, based on the total weight of the co-solvent system.
  • the water is present in an amount no greater than 60% by weight.
  • the pharmaceutical composition includes
  • propylene glycol and less than 10% by weight, propylene glycol.
  • compositions may be any suitable topical pharmaceutical preparation and may include solutions, lotions, ointments, mousses, foams, sprays, aerosols, shampoos and/or conditioners, gels, creams, pastes, and other preparations known in the art.
  • the composition may also include other ingredients such as preservatives, buffers, stabilisers, propellants and the like.
  • the pharmaceutical composition is a mousse composition.
  • the mousse composition may include a suitable propellant, for example hydrocarbons or chlorofluorocarbons.
  • the pharmaceutical composition may be a gel composition.
  • the gel composition may include a suitable gelling agent, e.g. a cellulose derivative. A hydroxy propyl cellulose, for example that sold under the trade designation Klucel M, has been found to be suitable.
  • the aerosol formulation may be a homogeneous, aqueous-alcoholic emulsion system.
  • the aerosol formulation upon actuation produces a stabilized, homogeneous, expandable foam which breaks easily with shear.
  • a composition of this type is sometimes referred to as a “mousse”.
  • the pharmaceutical composition according to the present invention may further include an effective amount of a skin penetrating agent.
  • Suitable skin penetrating agents include alcohols such as dodecanol and oleyl alcohol; amines, such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine; carboxylic acids, such as oleic acid, linoleic acid and linolenic acid; esters, such as dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate; and others, such as Azone, N methyl pyrollidone, bile salts and urea.
  • alcohols such as dodecanol and oleyl alcohol
  • amines such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine
  • carboxylic acids such as oleic acid, linoleic
  • compositions herein may be actuated using propellants known per se in the pharmaceutical or cosmetic fields.
  • propellants include hydrocarbons such as propane, isobutane or dimethyl ether and chlorofluorocarbons such as P-12, P114, and a 40:60 mixture thereof.
  • general purpose components ordinarily used in hair treatment compositions can be formulated, within a range which does not impair the effect of the present invention, including vitamins such as vitamin B.sub.6, vitamin E and derivatives thereof, and biotin; hair generating agents or hair generating aids such as panthothenic acid and derivatives thereof, glycylrrhetic acid and derivatives thereof, nicotinic acid esters such as benzyl nicotinate, cyclosporins, carpronium chloride, cepharanthine, oxendolone, diazoxide, minoxidil, and ethynylesteradiol; antibacterial agents such as hinokitiol, hexachlorophen, phenol, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, and bithionol; refrigerants such as
  • compositions for topical administration including, as the pharmaceutically active component,
  • a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and
  • the hair loss may be related to any of the forms of alopecia including male pattern alopecia.
  • Related indications may include weakening of hair strength, loss of hair colour and the like.
  • the pharmaceutically active component includes a minoxidil or a minoxidil salt, more preferably a minoxidil acetate, succinate or citrate salt.
  • composition includes
  • the apparent pH of each formulation was measured once prepared. The measured taken as the apparent pH due to the high proportion of organic modifiers in the formulations. Typically, 0.5% (w/w) glacial acetic acid (0.1M) would be used in the formulation, which would equate to a pH of 1.0 in an aqueous system when no other components are contributing to the pH of the solution.
  • 0.5% (w/w) glacial acetic acid (0.1M) would be used in the formulation, which would equate to a pH of 1.0 in an aqueous system when no other components are contributing to the pH of the solution.
  • the apparent pH of the final formulated solution was measured at 6.24.
  • Topical Minoxidil mousse 5% for hair treatment Minoxidil 5.00% Cetyl Alcohol 2.20% Stearyl Alcohol 1.00% Ethanol 51.8 Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Propylene Glycol 5.00% Propellant P75 4.30% Acetic Acid qs. pH 6.0 Purified water to total 100%
  • Topical Minoxidil lotion 8% for hair treatment Minoxidil 8.00% Ethanol 50.50% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Nitric Acid qs. pH 6.0 Propylene Glycol 7.30% Benzyl Alcohol 5.00% Purified Water to total 100%
  • the apparent pH of the final formulated solution was measured at 6.24.
  • Topical Minoxidil lotion 10% for hair treatment Minoxidil 10.00% Ethanol 48.0% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Acetic Acid qs. pH 6.0 Propylene Glycol 10.0% Benzyl Alcohol 5.00% Purified Water to total 100%
  • Topical Minoxidil lotion 10% for hair treatment Minoxidil 10.00% Ethanol 47.50% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Acetic Acid qs. pH 6.0 Benzyl Alcohol 15.00% Purified Water to total 100%
  • the apparent pH of the final formulated solutions was measured at 6.0 and 6.5 for formulations 3a and 3b, respectively.
  • Topical Minoxidil lotion 11% for hair treatment Minoxidil 11.00% Ethanol 44.20% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Acetic Acid qs. pH 6.0 Benzyl Alcohol 20.00% Purified Water to total 100%
  • Topical Minoxidil lotion 12% for hair treatment Minoxidil 12.00% Ethanol 42.7% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Acetic Acid qs. pH 6.0 Benzyl Alcohol 20.00% Purified Water to total 100%
  • Topical Minoxidil lotion 12% for hair treatment Minoxidil 12.00% Ethanol 42.7% Polysorbate 60 0.4% Polyoxyethylene lauryl alcohol 1.00% Acetic Acid qs. pH 6.0 Benzyl Alcohol 10.00% Propylene Glycol 10.00% Purified Water to total 100%
  • An aqueous gel was prepared by adding 0.75% (w/w) Klucel M (hydroxypropyl cellulose) to Example 4. The viscosity of the gel was measured at 2400 cPoise at 20° C.
  • Example 7 Investigations were carried out to determine which of the components present in Example 7 (10% (w/w) minoxidil solution) were contributing to the solubilisation of minoxidil. The investigation was split into three sections:
  • the solubility determination involved preparation of saturated solutions of minoxidil in the media of interest. These solutions were then filtered (0.45 ⁇ m) and analysed against a standard curve by means of direct UV spectroscopy.
  • the aqueous solubility of minoxidil was found to be 2.2 mg/mL.
  • the solubility of minoxidil was determined in each of the co-solvents, benzyl alcohol, glycerol, propylene glycol and ethanol. Additionally, the solubility of minoxidil was determined in 10% (w/w) solutions of each of the co-solvents, ethanol, propylene glycol and glycerol in water. A 4% (w/w) solution of benzyl alcohol was used since this was found to be the limit of the solubility of benzyl alcohol in water. The following table summarises the results of these studies.
  • Minoxidil base was used for these studies with the appropriate salt (acetate or HCl) formed in situ. As discussed above the use of low pH acetate buffers significantly increased the solubility of minoxidil.
  • the acid form of minoxidil has been shown to be much more soluble in an aqueous environment.
  • the use of co-solvents has been shown to enhance the solubility of the minoxidil free base.
  • the co-solvents may also enhance the solubility of the acid form.
  • the use of an appropriate salt enhances the solubility of the acid form of minoxidil. Therefore, a combination of these three factors may be used to optimise the solubility of minoxidil in a topical solution based formulation.

Abstract

A pharmaceutical composition for topical administration, including, as the pharmaceutically active component, at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; an acid in an amount to completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof; a solvent composition including at least two of water, a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.

Description

    BACKGROUND OF THE INVENTION
  • The present invention relates to a vehicle system for a pharmaceutical composition comprising a piperidinopyrimidine derivative. More particularly minoxidil and to a pharmaceutical composition incorporating the vehicle system. Minoxidil is a pharmaceutically active ingredient having several indications including use as a hair growth stimulant.
  • Minoxidil has poor solubility in water and ethanol and pharmaceutical preparations currently marketed only contain a small percentage of minoxidil. That is, below 5%.
  • Numerous formulations comprising minoxidil have been published in the prior art including U.S. Pat. Nos. 4,139,619, 4,820,512, 5,104,646, 5,225,189, 4,938,953, 4,596,812, 5,006,332, 5,156,836 and 5,643,942. Many of the formulations require (or would require where the amount of minoxidil is greater than 5%) a very high percentage (often in the range of 30 to 50%) of propylene glycol or a similar glycol product in order to improve the solubility of minoxidil. Due to the viscosity and tack of propylene glycol, large amounts of propylene glycol or similar agents in a composition are not pharmaceutically or cosmetically elegant and may be unacceptable to the consumer. In addition, high concentrations of propylene glycol may cause local irritation and hypersensitivity upon application to the scalp.
  • It would accordingly be a significant advance in the art if a composition could be provided which would permit the inclusion of an increased percentage of the active ingredient, but without the disadvantages associated with a high propylene glycol concentration.
  • Accordingly, it is an object of the present invention to overcome, or at least alleviate, one or more of the difficulties and deficiencies related to the prior art. These and other objects and features of the present invention will be clear from the following disclosure.
  • SUMMARY OF THE INVENTION
  • Accordingly, the present invention in a first aspect provides a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
  • at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
  • an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
  • a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.
  • Applicants have surprisingly discovered that by adjusting the acid concentration of the composition the solubility of the piperidinopyrimidine derivatives may be significantly increased without the necessity of utilising large amounts of propylene glycol or optionally by excluding propylene glycol altogether. Accordingly the total amount of active in the composition may be significantly increased. In a preferred form, the pharmaceutically active component is present in amounts of approximately 5 to 25% by weight, preferably approximately 5 to 15% by weight, more preferably approximately 7.5 to 12% by weight.
  • Preferably the piperidinopyrimidine derivative is minoxidil. Preferably the minoxidil is present in the form of a salt. The salt may include acetate, citrate, succinate, benzoate, hydrochloride, sulphate, phosphate or lactate. Preferably an acetate or lactate salt of minoxidil is used. The acetate or lactate salts may exhibit enhanced solubility and improve the ability to incorporate increased amounts of the active component in the composition.
  • In a preferred form the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less. The apparent pH of the composition is preferably between approximately 5.0 to 7.0, more preferably between 6.0 to 6.5. Any suitable acid may be used to adjust the pH, including mineral acids, such as hydrochloric acid, sulphuric acid, nitric acid and phosphoric acid, or organic acids such as citric acid, acetic acid, succinic acid, or maleic acid, or mixtures thereof. Acetic acid or lactic acid is preferred.
  • In a preferred form the acid is present at a level that provides at least 0.01 Normal acid. Alternatively, the acid is present in an amount equal to, or greater than, the amount of the piperidinopyrimidine derivative in Normal amounts.
  • Preferably the lower alcohol is ethanol. The ratio of water to ethanol is preferably from approximately 9:1 to 1;9, more preferably approximately 1:1 to 1:3, by volume.
  • Preferably, the co-solvent includes benzyl alcohol. The benzyl alcohol may be present in amounts of approximately 2.5 to 95% by weight, preferably approximately 5 to 40% by weight, based on the total weight of the pharmaceutical composition.
  • Alternatively, or in addition the co-solvent may include a polyhydric alcohol, for example a polyol selected from the group consisting of 1,3-butylene glycol, propylene glycol, preferably glycol 200 (PEG 200), polyethylene glycol 400 (PEG 400), hexylene glycol and dipropylene glycol, or glycerol. When propylene glycol is present, it may be present in amounts of approximately 10% by weight or less, preferably approximately 5% by weight, or less.
  • In compositions comprising 5% of minoxidil or greater, it is preferred to include benzyl alcohol in the composition. The benzyl alcohol may be present in amounts of up to 85% by weight, based on the total weight of the pharmaceutical composition.
  • In a preferred form the co-solvent system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight, based on the total weight of the co-solvent system.
  • In a preferred form the water is present in an amount no greater than 60% by weight.
  • In a preferred aspect, the pharmaceutical composition includes
  • approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;
  • approximately 88 to 95% by weight of a solvent composition including
      • approximately 10 to 70% by weight of ethanol,
      • approximately 2.5 to 85% by weight of benzyl alcohol;
  • and less than 10% by weight, propylene glycol.
  • The final presentation of the composition may be any suitable topical pharmaceutical preparation and may include solutions, lotions, ointments, mousses, foams, sprays, aerosols, shampoos and/or conditioners, gels, creams, pastes, and other preparations known in the art. The composition may also include other ingredients such as preservatives, buffers, stabilisers, propellants and the like.
  • Preferably the pharmaceutical composition is a mousse composition. The mousse composition may include a suitable propellant, for example hydrocarbons or chlorofluorocarbons. Alternatively the pharmaceutical composition may be a gel composition. The gel composition may include a suitable gelling agent, e.g. a cellulose derivative. A hydroxy propyl cellulose, for example that sold under the trade designation Klucel M, has been found to be suitable.
  • Where an aerosol formulation is used, the aerosol formulation may be a homogeneous, aqueous-alcoholic emulsion system. The aerosol formulation upon actuation produces a stabilized, homogeneous, expandable foam which breaks easily with shear. A composition of this type is sometimes referred to as a “mousse”.
  • In a further preferred aspect, the pharmaceutical composition according to the present invention may further include an effective amount of a skin penetrating agent.
  • Suitable skin penetrating agents include alcohols such as dodecanol and oleyl alcohol; amines, such as isopropyl amine, diisopropyl amine, triethyl amine, triethanol amine, diisopropanolamine and ethylene diamine; carboxylic acids, such as oleic acid, linoleic acid and linolenic acid; esters, such as dibutyl sebacate, dibutyl phthalate, butyl benzoate and ethyl caprate; and others, such as Azone, N methyl pyrollidone, bile salts and urea.
  • All of the compositions herein may be actuated using propellants known per se in the pharmaceutical or cosmetic fields. Such propellants include hydrocarbons such as propane, isobutane or dimethyl ether and chlorofluorocarbons such as P-12, P114, and a 40:60 mixture thereof.
  • In the pharmaceutical composition according to the present invention, in addition to the above essential components, general purpose components ordinarily used in hair treatment compositions can be formulated, within a range which does not impair the effect of the present invention, including vitamins such as vitamin B.sub.6, vitamin E and derivatives thereof, and biotin; hair generating agents or hair generating aids such as panthothenic acid and derivatives thereof, glycylrrhetic acid and derivatives thereof, nicotinic acid esters such as benzyl nicotinate, cyclosporins, carpronium chloride, cepharanthine, oxendolone, diazoxide, minoxidil, and ethynylesteradiol; antibacterial agents such as hinokitiol, hexachlorophen, phenol, benzalkonium chloride, cetylpyridinium chloride, undecylenic acid, trichlorocarbanilide, and bithionol; refrigerants such as menthol; drugs such as salicylic acid, zinc and derivatives, thereof, and lactic acid and alkyl esters thereof; amino acids such as arginine; oil components such as olive oil, squalane, fluid paraffin, isopropyl myristate, higher fatty acids, and higher alcohols; perfumes; antioxidants; UV-ray absorbers; dyes; humectants; thickeners; perfumes; colour additives and the like.
  • In a still further aspect of the present invention, there is provided a method for the treatment of hair loss and related indications in humans, which method includes
  • providing
  • a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
      • at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
  • an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
  • a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and
  • applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.
  • The hair loss may be related to any of the forms of alopecia including male pattern alopecia. Related indications may include weakening of hair strength, loss of hair colour and the like.
  • Preferably the pharmaceutically active component includes a minoxidil or a minoxidil salt, more preferably a minoxidil acetate, succinate or citrate salt.
  • More preferably the pharmaceutical composition includes
  • approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;
  • approximately 88 to 95% by weight of a solvent composition including
      • approximately 10 to 70% by weight of ethanol,
      • approximately 2.5 to 85% by weight of benzyl alcohol; and less than 10% by weight, propylene glycol.
  • The present invention will now be more fully described with reference to the accompanying figures and examples. It should be understood, however, that the description following is illustrative only and should not be taken in any way as a restriction on the generality of the invention described above.
  • In each of the following examples it was necessary to add an appropriate amount of acid to ensure equivalent acid normality. The standard technique for such an adjustment is to measure the apparent pH of the solution.
  • In the examples, the apparent pH of each formulation was measured once prepared. The measured taken as the apparent pH due to the high proportion of organic modifiers in the formulations. Typically, 0.5% (w/w) glacial acetic acid (0.1M) would be used in the formulation, which would equate to a pH of 1.0 in an aqueous system when no other components are contributing to the pH of the solution.
  • EXAMPLE 1
  • Topical Minoxidil lotion 5% with no propylene glycol
    Minoxidil 5.00%
    Ethanol 60.3%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol 1.00%
    Acetic Acid 0.6
    Purified Water to total 100%
  • The apparent pH of the final formulated solution was measured at 6.24.
  • EXAMPLE 2
  • Topical Minoxidil mousse 5% for hair treatment
    Minoxidil 5.00%
    Cetyl Alcohol 2.20%
    Stearyl Alcohol 1.00%
    Ethanol 51.8
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol 1.00%
    Propylene Glycol 5.00%
    Propellant P75 4.30%
    Acetic Acid qs. pH 6.0
    Purified water to total 100%
  • EXAMPLE 3
  • Topical Minoxidil lotion 8% for hair treatment
    Minoxidil 8.00%
    Ethanol 50.50%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol 1.00%
    Nitric Acid qs. pH 6.0
    Propylene Glycol 7.30%
    Benzyl Alcohol 5.00%
    Purified Water to total 100%
  • EXAMPLE 4
  • Topical 8% (w/w) Minoxidil solution
    Minoxidil 8.0%
    Ethanol 50.5% 
    Crilet 3 0.4%
    Teric 12A4 1.0%
    Glacial Acetic Acid 0.3%
    Propylene Glycol 7.5%
    Benzyl Alcohol 5.0%
    Purified Water to total 100%
  • The apparent pH of the final formulated solution was measured at 6.24.
  • EXAMPLE 5
  • Topical Minoxidil lotion 10% for hair treatment
    Minoxidil 10.00% 
    Ethanol 48.0%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol 1.00%
    Acetic Acid qs. pH 6.0
    Propylene Glycol 10.0%
    Benzyl Alcohol 5.00%
    Purified Water to total 100%
  • EXAMPLE 6
  • Topical Minoxidil lotion 10% for hair treatment
    Minoxidil 10.00%
    Ethanol 47.50%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol  1.00%
    Acetic Acid qs. pH 6.0
    Benzyl Alcohol 15.00%
    Purified Water to total 100%
  • EXAMPLE 7
  • Topical 10% (w/w) Minoxidil solution
    Formulation 3a Formulation 3b
    Minoxidil 10.00% 10.00%
    Ethanol 46.80% 44.20%
    Crillet 3  0.4%  0.4%
    Teric 12A4  1.0%  1.0%
    Glacial Acetic Acid  1.0%  0.3%
    Propylene Glycol  10.0% nil
    Benzyl Alcohol  5.00%  2.00%
    Purified Water to total 100% to total 100%
  • The apparent pH of the final formulated solutions was measured at 6.0 and 6.5 for formulations 3a and 3b, respectively.
  • EXAMPLE 8
  • Topical Minoxidil lotion 11% for hair treatment
    Minoxidil 11.00%
    Ethanol 44.20%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol  1.00%
    Acetic Acid qs. pH 6.0
    Benzyl Alcohol 20.00%
    Purified Water to total 100%
  • EXAMPLE 9
  • Topical Minoxidil lotion 12% for hair treatment
    Minoxidil 12.00%
    Ethanol  42.7%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol  1.00%
    Acetic Acid qs. pH 6.0
    Benzyl Alcohol 20.00%
    Purified Water to total 100%
  • EXAMPLE 10
  • Topical Minoxidil lotion 12% for hair treatment
    Minoxidil 12.00%
    Ethanol  42.7%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol  1.00%
    Acetic Acid qs. pH 6.0
    Benzyl Alcohol 10.00%
    Propylene Glycol 10.00%
    Purified Water to total 100%
  • EXAMPLE 11 Topical Minoxidil Lotion 12% for Hair Treatment
  • Minoxidil 12.00%
    Ethanol  42.7%
    Polysorbate 60  0.4%
    Polyoxyethylene lauryl alcohol  1.00%
    Acetic Acid qs. pH 6.0
    Benzyl Alcohol 15.00%
    Propylene Glycol  5.00%
    Purified Water to total 100%
  • There appear to be no obvious gross stability issues associated with any of the formulations. The levels of minoxidil were assayed in formulations 1 and 3a after they had been stored for one and three months at 4° C. and 50° C. No measurable loss in potency was observed.
  • An aqueous gel was prepared by adding 0.75% (w/w) Klucel M (hydroxypropyl cellulose) to Example 4. The viscosity of the gel was measured at 2400 cPoise at 20° C.
  • EXAMPLE 12
  • Investigations were carried out to determine which of the components present in Example 7 (10% (w/w) minoxidil solution) were contributing to the solubilisation of minoxidil. The investigation was split into three sections:
      • Effect of Co-solvent
      • Effect of pH
      • Effect of Salt
  • The solubility determination involved preparation of saturated solutions of minoxidil in the media of interest. These solutions were then filtered (0.45 μm) and analysed against a standard curve by means of direct UV spectroscopy.
  • Aqueous Unbuffered Solubility of Minoxidil
  • The aqueous solubility of minoxidil was found to be 2.2 mg/mL.
  • Effect of Co-Solvent
  • The solubility of minoxidil was determined in each of the co-solvents, benzyl alcohol, glycerol, propylene glycol and ethanol. Additionally, the solubility of minoxidil was determined in 10% (w/w) solutions of each of the co-solvents, ethanol, propylene glycol and glycerol in water. A 4% (w/w) solution of benzyl alcohol was used since this was found to be the limit of the solubility of benzyl alcohol in water. The following table summarises the results of these studies.
    Sample Minoxidil Solubility (mg/mL)
    Benzyl alcohol 125.1
    Glycerol 47.3
    Propylene Glycol 86.9
    Ethanol 18.8
    10% (w/w) Ethanol/Water 3.4
    10% (w/w) Propylene Glycol/Water 3.0
     4% (w/w) Benzyl Alcohol/Water 4.5
    10% (w/w) Glycerol/Water 2.7
  • Analysis indicated that of the systems studied only the use of pure benzyl alcohol would result in the desired 10% (w/w) minoxidil solution.
  • Effect of Apparent pH
  • Attempts were made to prepare saturated solutions of minoxidil in acetate buffers at apparent pH's 2.5, 3.5, 4.6, 5.0 and 6.0. Saturated solutions were achieved with those pHs above the pKa of minoxidil (4.61), the results of which are summarised in the following table.
    pH Minoxidil Solubility (mg/mL)
    6.0 2.5
    5.0 4.1
    4.6 11.3
  • It was not possible to determine the solubility limits of minoxidil at pH's below it's pKa, as minoxidil was found to be extremely soluble in acidic media and the buffer used had insufficient capacity to avoid the drift in pH observed with additions of minoxidil to the solution. The maximum minoxidil concentration studied was 22 mg/mL and was found to be completely soluble in pH 2.5 and 3.5 solutions at this concentration. The following table outlines the maximum solubility that would be expected in an acidic aqueous media knowing the solubility of the base form of minoxidil is 2.2 mg/mL and assuming infinite solubility of the acid form of minoxidil.
    pH Minoxidil Solubility (mg/mL)
    3.6 22.0
    3.0 87.6
    2.6 220.0
    2.0 876.0

    Effect of Salt
  • Minoxidil base was used for these studies with the appropriate salt (acetate or HCl) formed in situ. As discussed above the use of low pH acetate buffers significantly increased the solubility of minoxidil.
  • The major factors affecting the solubilisation of minoxidil in an aqueous environment were found to be:
  • The type and proportion of co-solvents present in the formulation
  • The pH of the final formulated solution
  • The amount of minoxidil used
  • The acid form of minoxidil has been shown to be much more soluble in an aqueous environment. The use of co-solvents has been shown to enhance the solubility of the minoxidil free base. The co-solvents may also enhance the solubility of the acid form. The use of an appropriate salt enhances the solubility of the acid form of minoxidil. Therefore, a combination of these three factors may be used to optimise the solubility of minoxidil in a topical solution based formulation.
  • All the above examples were stored at room temperature and no crystallisation or precipitation was observed for at least 10 days.
  • Please note all percentages are based upon the total weight of the composition unless otherwise specified.
  • It will be understood that the invention disclosed and defined in this specification extends to all alternative combinations of two or more of the individual features mentioned or evident from the text or drawings. All of these different combinations constitute various alternative aspects of the invention.
  • It will also be understood that the term “comprises” (or its grammatical variants) as used in this specification is equivalent to the term “includes” and should not be taken as excluding the presence of other elements or features.

Claims (25)

1. A pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof
a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight.
2. A pharmaceutical composition according to claim 1, wherein the acid is added in an amount sufficient to provide an apparent pH to the composition of approximately 7.0 or less.
3. A pharmaceutical composition according to claim 1, wherein the pharmaceutically active component is present in an amount of from approximately 5 to 25% by weight, based on the total weight of the pharmaceutical composition.
4. A pharmaceutical composition according to claim 3, wherein the pharmaceutically active component is present in an amount of approximately 7.5 to 12% by weight, based on the total weight of the pharmaceutical composition.
5. A pharmaceutical composition according to claim 1, wherein the pharmaceutically active component is minoxidil or a salt thereof.
6. A pharmaceutical composition according to claim 2, wherein the acid provides to the composition an apparent pH in the range of approximately 5.0 to 7.0.
7. A pharmaceutical composition according to claim 2, wherein the acid is a mineral or organic acid.
8. A pharmaceutical composition according to claim 7, wherein the acid includes acetic or lactic acid.
9. A pharmaceutical composition according to claim 1, wherein the solvent composition includes water and ethanol in a range of approximately 1:1 to 1:3 by volume.
10. A pharmaceutical composition according to claim 1, wherein the co-solvent includes benzyl alcohol.
11. A pharmaceutical composition according to claim 1, wherein the solvent composition system includes water and benzyl alcohol wherein the benzyl alcohol is in an amount of approximately 40 to 100% by weight based on the total weight of the co-solvent system.
12. A pharmaceutical composition according to claim 1, wherein the water is present in an amount no greater than approximately 60% by weight based on the total weight of the co-solvent system.
13. A pharmaceutical composition according to claim 1, wherein the co-solvent includes an alkylene glycol.
14. A pharmaceutical composition according to claim 13, wherein the alkylene glycol is selected from one or more of the group consisting of glycerol, 1,3-butylene or propylene glycol.
15. A pharmaceutical composition according to claim 1, wherein the acid is present at a level that provides at least 0.01 Normal acid.
16. A pharmaceutical composition according to claim 1, wherein the acid is present in an amount equal to or greater than the amount of the piperidinopyrimidine derivative in Normal amounts.
17. A pharmaceutical composition according to claim 1, wherein the solvent system includes water and ethanol in a range of approximately 9:1 to 1:9 by volume.
18. A pharmaceutical composition according to claim 5, wherein the pharmaceutically active component is a minoxidil salt.
19. A pharmaceutical composition according to claim 18, wherein the minoxidil salt is a minoxidil acetate or lactate salt.
20. A pharmaceutical composition according to claim 1, including
approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil acid salt;
approximately 88 to 95% by weight of a solvent composition including
approximately 10 to 70% by weight of ethanol,
approximately 2.5 to 85% by weight of benzyl alcohol;
and less than 10% by weight, propylene glycol.
21. A method for the treatment of hair loss and related indications in humans, which method includes
providing
a pharmaceutical composition for topical administration, including, as the pharmaceutically active component,
at least 5% by weight, based on the total weight of the composition of a piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
an acid in an amount to substantially completely solubilise the piperidinopyrimidine derivative or a pharmaceutically acceptable salt thereof;
a solvent composition including a solvent selected from water and/or a lower alcohol and a co-solvent selected from one or more of the group consisting of aromatic and polyhydric alcohols; wherein when the co-solvent includes propylene glycol, it is present in an amount of less than approximately 10% by weight; and
applying topically to the human scalp a therapeutically or prophylactically effective amount of the pharmaceutical composition.
22. A method according to claim 21, wherein the pharmaceutically active component includes minoxidil or a minoxidil salt.
23. A method according to claim 22, wherein the minoxidil salt is a minoxidil acetate or lactate salt.
24. A method according to claim 21, wherein the pharmaceutical composition includes
approximately 5 to 12% by weight, based on the total weight of the composition, of a minoxidil or a minoxidil salt;
approximately 88 to 95% by weight of a solvent composition including
approximately 10 to 70% by weight of ethanol,
approximately 2.5 to 85% by weight of benzyl alcohol;
and less than 10% by weight, propylene glycol.
25. A pharmaceutical composition according to claim 1, substantially as herein before described with reference to any one of the examples.
US10/949,116 1998-04-22 2004-09-10 Pharmaceutical composition Abandoned US20050037060A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/949,116 US20050037060A1 (en) 1998-04-22 2004-09-10 Pharmaceutical composition

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AUPP3107A AUPP310798A0 (en) 1998-04-22 1998-04-22 Vehicle system for a composition comprising a piperidinopyrimidine derivative
AUPP3107 1998-04-22
WOPCT/AU99/00294 1999-04-20
PCT/AU1999/000294 WO1999053923A1 (en) 1998-04-22 1999-04-20 Pharmaceutical composition
US67387200A 2000-12-04 2000-12-04
US10/949,116 US20050037060A1 (en) 1998-04-22 2004-09-10 Pharmaceutical composition

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US67387200A Continuation 1998-04-22 2000-12-04

Publications (1)

Publication Number Publication Date
US20050037060A1 true US20050037060A1 (en) 2005-02-17

Family

ID=3807366

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/124,197 Expired - Lifetime US6946120B2 (en) 1998-04-22 2002-04-16 Pharmaceutical composition
US10/949,116 Abandoned US20050037060A1 (en) 1998-04-22 2004-09-10 Pharmaceutical composition

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/124,197 Expired - Lifetime US6946120B2 (en) 1998-04-22 2002-04-16 Pharmaceutical composition

Country Status (13)

Country Link
US (2) US6946120B2 (en)
EP (2) EP1073439B1 (en)
JP (3) JP3710380B2 (en)
AT (1) ATE331517T1 (en)
AU (1) AUPP310798A0 (en)
BR (1) BR9909796B1 (en)
CA (1) CA2328950C (en)
CY (1) CY1120513T1 (en)
DE (1) DE69932158T2 (en)
DK (2) DK1695708T3 (en)
ES (2) ES2268856T3 (en)
PT (2) PT1073439E (en)
WO (1) WO1999053923A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078905A1 (en) * 2006-12-22 2008-07-03 Cj Cheiljedang Corporation Compositions for external use containing minoxidil for hair growth which have an improved skin permeability
US20090016970A1 (en) * 2007-02-22 2009-01-15 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
WO2014184173A1 (en) * 2013-05-14 2014-11-20 Montero Gida Sanayi Ve Ticaret A.S. Hair care formulations

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
AUPP310798A0 (en) 1998-04-22 1998-05-14 Soltec Research Pty Ltd Vehicle system for a composition comprising a piperidinopyrimidine derivative
JPH11349451A (en) * 1998-06-08 1999-12-21 Taisho Pharmaceut Co Ltd Hair grower
US8263580B2 (en) 1998-09-11 2012-09-11 Stiefel Research Australia Pty Ltd Vitamin formulation
US6342496B1 (en) * 1999-03-01 2002-01-29 Sepracor Inc. Bupropion metabolites and methods of use
US20030170191A1 (en) * 2000-04-07 2003-09-11 Koji Imamura Hair growth stimulant compositions with sustained action
HUP0300417A2 (en) * 2000-04-07 2003-08-28 Taisho Pharmaceutical Co., Ltd. Hair growth stimulant compositions and method for their stabilization by inhibition of precipitation of crystals
JP4892786B2 (en) * 2000-04-07 2012-03-07 大正製薬株式会社 Sustainable hair growth preparation
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
US7442369B1 (en) * 2000-08-09 2008-10-28 Mcneil Ab Compositions of minoxidil
AUPR048600A0 (en) * 2000-10-02 2000-10-26 Soltec Research Pty Ltd Pharmaceutical vehicle
JP4189223B2 (en) * 2001-05-15 2008-12-03 大正製薬株式会社 Minoxidil combination liquid composition
SE0104421D0 (en) 2001-12-21 2001-12-21 Ponsus Pharma Ab New composition
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
MXPA05004278A (en) 2002-10-25 2005-10-05 Foamix Ltd Cosmetic and pharmaceutical foam.
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US8119150B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
EA009031B1 (en) 2003-01-24 2007-10-26 Стифел Рисерч Оустрэйлиа Пти Лтд. Clindamycin phosphate based foam
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US7186416B2 (en) 2003-05-28 2007-03-06 Stiefel Laboratories, Inc. Foamable pharmaceutical compositions and methods for treating a disorder
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
EA200600666A1 (en) 2003-09-29 2006-10-27 Этена Хелткеа Инк. GEL AND WOODY COMPOSITIONS WITH HIGH ALCOHOL CONTENT
GB0323908D0 (en) * 2003-10-11 2003-11-12 Nupharm Lab Ltd Pharmaceutical foam formulation
AU2003299882A1 (en) * 2003-12-22 2005-08-03 Regrowth, Llc Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20050163811A1 (en) * 2004-01-23 2005-07-28 Richard Lee Topical solutions comprising high concentrations of piperidinopyrimidine derivatives and methods of use thereof
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
DE102004062775A1 (en) 2004-12-21 2006-06-29 Stockhausen Gmbh Alcoholic pump foam
PL1858323T3 (en) 2005-03-07 2018-02-28 Deb Ip Limited High alcohol content foaming compositions with silicone-based surfactants
WO2007054818A2 (en) 2005-05-09 2007-05-18 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
PL2526930T3 (en) * 2005-06-01 2014-05-30 Glaxosmithkline Ip Dev Ltd Vitamin formulation
US8147815B2 (en) * 2005-12-16 2012-04-03 Celmatrix Corporation Topical administration carrier composition and therapeutic formulations comprising same
AU2007273935B2 (en) 2006-03-31 2011-08-18 Stiefel Research Australia Pty Ltd Foamable suspension gel
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8580860B2 (en) * 2007-02-23 2013-11-12 Gojo Industries, Inc. Foamable alcoholic composition
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
JP5420946B2 (en) 2009-03-23 2014-02-19 富士フイルム株式会社 Minoxidil aqueous composition containing bile acids
JP2010222317A (en) * 2009-03-25 2010-10-07 Shiseido Co Ltd Oil-in-water type emulsified cosmetic
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9364485B2 (en) 2009-08-31 2016-06-14 Dr. Reddy's Laboratories Ltd. Topical formulations comprising a steroid
MX359879B (en) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Topical tetracycline compositions.
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US20110189114A1 (en) * 2010-01-29 2011-08-04 Nyangenya Maniga minoxidil composition and non-aerosol, non-spray foam method of delivery therefor
US9271917B2 (en) 2010-01-29 2016-03-01 Nyangenya Maniga Method and apparatus for delivery of a measured dosage of a non-aerosol, non-spray foam composition of minoxidil
WO2012040342A2 (en) * 2010-09-21 2012-03-29 Conrex Pharmaceutical Corporation Restoration of hair
AU2011338530B2 (en) 2010-12-06 2017-06-15 Follica, Inc. Methods for treating baldness and promoting hair growth
US9717741B2 (en) 2012-10-11 2017-08-01 Anaplasi Pharmaceuticals Llc Method and compositions for treating psoriasis
ES2793404T3 (en) 2012-10-11 2020-11-13 Anaplasi Pharmaceuticals Llc Method and compositions for the treatment of psoriasis
WO2014122436A1 (en) 2013-02-07 2014-08-14 Cipla House Topical pharmaceutical compositions comprising minoxidil
US8642097B1 (en) 2013-03-19 2014-02-04 Nyangenya Maniga Natural product energy drink and method of use thereof
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
US9474699B2 (en) * 2014-03-31 2016-10-25 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of a basic benefit agent
US9468606B2 (en) 2014-03-31 2016-10-18 Johnson & Johnson Consumer Inc. Compostions and methods for enhancing the topical application of an acidic benefit agent
CA2950313A1 (en) 2014-06-16 2015-12-23 Johnson & Johnson Consumer Inc. Compositions and methods for enhancing the topical application of a color cosmetic
WO2015195304A1 (en) 2014-06-17 2015-12-23 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for enhancing the topical application of a benefit agent including powder to liquid particles and a second powder
US9675537B2 (en) 2014-06-30 2017-06-13 Johnson & Johnson Consumer Inc. Hair growth composition and method
JP7072346B2 (en) * 2015-03-27 2022-05-20 大正製薬株式会社 Lotion
WO2016159916A1 (en) * 2015-03-31 2016-10-06 Ogi̇g Sağlik Ürünleri̇ Ve Hi̇zmetleri̇ Sanayi̇ Ti̇caret Li̇mi̇ted Şi̇rketi̇ A foamy pharmaceutical formulation used in dermatological diseases
MX2017014683A (en) * 2015-05-18 2018-03-14 Perry Thrower Angelo Hair regrowth treatment and growth stimulant.
EP3355799B1 (en) 2015-09-27 2021-09-01 Follica, Inc. Needling device and drug applicator
ES2809704T3 (en) 2015-10-06 2021-03-05 Assos Ilac Kimya Gida Ueruenleri Ueretim Ve Tic A S Topical composition of minoxidil
US10561593B2 (en) * 2015-12-28 2020-02-18 Johnson & Johnson Consumer Inc. Hair growth composition and method
CN105434352A (en) * 2015-12-31 2016-03-30 浙江万晟药业有限公司 Minoxidil foaming agent as well as preparation method and application thereof
JP2018048105A (en) * 2016-01-22 2018-03-29 大正製薬株式会社 Composition for external use
JP2018048104A (en) * 2016-01-22 2018-03-29 大正製薬株式会社 Composition for external use
JP6848565B2 (en) * 2016-03-30 2021-03-24 大正製薬株式会社 Aerosol agent
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
JP7366515B2 (en) * 2016-09-15 2023-10-23 大正製薬株式会社 External composition
US9962444B2 (en) 2016-09-27 2018-05-08 Shane Malek Pharmacokinetically extended action topical hair growth formulation, and administration method
US10702495B2 (en) 2017-02-20 2020-07-07 Nexien Biopharma, Inc. Method and compositions for treating dystrophies and myotonia
JP6990992B2 (en) 2017-05-25 2022-01-12 フクダ電子株式会社 Biological signal recording device and its control method
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
JP2019210268A (en) * 2018-05-30 2019-12-12 ダイヤ製薬株式会社 External preparation and method for producing external preparation
EP3801734A4 (en) 2018-05-30 2022-03-16 Follica, Inc. Methods for promoting hair growth
EP3750528A1 (en) 2019-06-11 2020-12-16 Nexien Biopharma, Inc. Compositions for treating dystrophies and myotonia
WO2020263115A1 (en) 2019-06-28 2020-12-30 Общество С Ограниченной Ответственностью "Регеус" Agent for promoting hair growth
EP3886799B1 (en) 2019-08-07 2023-11-15 Aneira Pharma, Inc. Compositions for the treatment of hair loss
BR102021003531A2 (en) 2021-02-24 2022-08-30 Eurofarma Laboratorios S.A. FOAMBLE TOPICAL PHARMACEUTICAL COMPOSITION

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515836A (en) * 1894-03-06 Basin-clamp
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4272516A (en) * 1976-11-08 1981-06-09 Societa Italo-Britannica-L. Manetti-H. Roberts Co. Process for improving transcutaneous and transfollicular absorption of cosmetic compositions
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4820512A (en) * 1986-08-07 1989-04-11 L'oreal Composition in the form of a gel for inducing and stimulating hair growth and for decreasing their loss, based on piperidinopyrimidine derivatives
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4866067A (en) * 1987-12-07 1989-09-12 Ricerche De Schiena s.n.c del Dr. Michele Giuseppe Di Schiena & C. 6-piperidino-2,4-diaminopyrimidine-3-oxide salt of 3-carboxypyridine n-oxide and topical, related compositions
US4882182A (en) * 1987-01-08 1989-11-21 Soltec Research Pty. Ltd. Aerosol product
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US4938953A (en) * 1988-08-09 1990-07-03 The Upjohn Company Self-preserving conditioning shampoo formulation
US4981678A (en) * 1983-10-24 1991-01-01 Soltec Research Pty., Ltd. Foamable biocide composition
US5006332A (en) * 1988-06-17 1991-04-09 L'oreal Composition for inducing and stimulating the growth of hair and/or retarding its loss, based on an amphoteric surface-active agent and on a pyrimidine derivative
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US5104646A (en) * 1989-08-07 1992-04-14 The Procter & Gamble Company Vehicle systems for use in cosmetic compositions
US5156836A (en) * 1987-10-02 1992-10-20 Shiseido Company Ltd. Hair revitalizing tonic composition
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US5225189A (en) * 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5516504A (en) * 1990-09-03 1996-05-14 Soltec Research Pty. Ltd. Concentrated water-free aerosol space spray
US5571841A (en) * 1986-12-23 1996-11-05 Tristrata Technology, Inc. Method of treating wrinkles using mandelic acid
US5578599A (en) * 1990-08-10 1996-11-26 The Upjohn Company Stimulation of hair growth with minoxidil and a 5α-reductase inhibitor
US5643942A (en) * 1986-08-08 1997-07-01 The Upjohn Company Methods, composition and solutions for treating alopecia
US5753216A (en) * 1991-03-19 1998-05-19 The Procter & Gamble Company Hair care compositions having styling/conditioning agent and plasticizer
US5783202A (en) * 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
US5788155A (en) * 1996-06-28 1998-08-04 S. C. Johnson & Son, Inc. Air freshener dispenser device with dual cartridge capacity
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5935554A (en) * 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6255313B1 (en) * 1997-01-23 2001-07-03 Taisho Pharmaceutical Co., Ltd. Sustained release hair growth composition
US6267949B1 (en) * 1997-05-20 2001-07-31 Soltec Research Pty Ltd. Sunscreen composition
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030157046A1 (en) * 2000-04-07 2003-08-21 Koji Imamura Minoxidil-containing preparations
US6946120B2 (en) * 1998-04-22 2005-09-20 Connetics Australia Pty. Ltd. Pharmaceutical composition

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3280344D1 (en) * 1981-11-09 1991-07-25 Gail S Bazzano USE OF RETINOIDES AND MINOXIDIL (2,4-DIAMINO-6-PIPERIDINO-PYRIMIDINE-3-OXIDE) TO IMPROVE THE GROWTH OF HUMAN HEAD HAIR AND TO TREAT CERTAIN TYPES OF ALOPECIA.
WO1986000196A1 (en) 1984-06-21 1986-01-16 Soltec Research Pty. Ltd. Aerosol product
JPS61197161A (en) 1985-02-25 1986-09-01 Amada Co Ltd Dressing device
IT1201436B (en) * 1985-07-19 1989-02-02 Vincenzo Zappia TOPICAL SLOW RELEASE FORMULATIONS
DE3781034T2 (en) * 1986-06-13 1993-02-18 Procter & Gamble TOPICAL PHARMACEUTICAL PREPARATION WITH BETTER PENETRAPHABILITY.
AU8025787A (en) 1986-09-12 1988-04-07 Upjohn Company, The Foams for delivery of minoxidil
JPS63150211A (en) 1986-12-15 1988-06-22 Taisho Pharmaceut Co Ltd External drug compounded with minoxidil
AU618517B2 (en) * 1986-12-23 1992-01-02 Eugene J. Van Scott Additives enhancing topical actions of therapeutic agents
JP2810041B2 (en) 1987-09-09 1998-10-15 株式会社資生堂 Hair restorer for scalp and hair
JPH0745387B2 (en) 1987-09-09 1995-05-17 株式会社資生堂 Hair growth and hair growth promoter
JP2810040B2 (en) * 1987-09-09 1998-10-15 株式会社資生堂 Hair restorer for scalp and hair
ATE90195T1 (en) 1988-02-18 1993-06-15 Upjohn Co MINOXIDIL GEL.
AU619256B2 (en) 1988-03-03 1992-01-23 Connetics Australia Pty Ltd Acne treatment
ZA94170B (en) 1993-01-20 1995-03-15 Soltec Res Pty Ltd Ectoparasiticidal formulation
JPH0748230A (en) * 1993-07-31 1995-02-21 Hideo Horiuchi Production of hair tonic
FR2717683B1 (en) 1994-03-22 1996-06-28 Fabre Pierre Cosmetique Hair composition based on minoxidil.
GB9504265D0 (en) 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
FR2736824B1 (en) * 1995-07-18 1997-10-10 Fabre Pierre Dermo Cosmetique MINOXIDIL HAIR COMPOSITION WITH LOW FAT SOLVENT CONTENT
JPH0971513A (en) 1995-09-07 1997-03-18 Taisho Pharmaceut Co Ltd Hair tonic
JP4467085B2 (en) * 1996-01-05 2010-05-26 大正製薬株式会社 Hinokitiol-containing composition
JPH09188629A (en) 1996-01-06 1997-07-22 Pola Chem Ind Inc Medicine for inhibiting antibody-producing cell and composition containing the same
US5838669A (en) 1996-08-28 1998-11-17 At&T Corp. Method of synchronizing satellite switched CDMA communication system
JP3061575B2 (en) 1996-10-17 2000-07-10 日立建機株式会社 Drilling rig
JPH10158782A (en) 1996-12-05 1998-06-16 Nkk Corp Steel sheet for shadow mask excellent in pierceability and press formability at the time of photo etching and its production
JPH10265343A (en) 1997-01-23 1998-10-06 Taisho Pharmaceut Co Ltd Sustained release hair growing agent
JPH10279437A (en) * 1997-03-31 1998-10-20 Shiseido Co Ltd Hair cosmetic
AUPO983897A0 (en) 1997-10-17 1997-11-06 Soltec Research Pty Ltd Topical antifungal composition
JPH11302131A (en) * 1998-04-15 1999-11-02 Shiseido Co Ltd Cosmetic for scalp and hair
JPH11349451A (en) 1998-06-08 1999-12-21 Taisho Pharmaceut Co Ltd Hair grower
AUPP583198A0 (en) 1998-09-11 1998-10-01 Soltec Research Pty Ltd Mousse composition
AUPQ002999A0 (en) 1999-04-29 1999-05-20 Soltec Research Pty Ltd Non-aqueous shampoo composition
JP4780429B2 (en) 2000-04-07 2011-09-28 大正製薬株式会社 Minoxidil-containing preparation
HUP0300417A2 (en) 2000-04-07 2003-08-28 Taisho Pharmaceutical Co., Ltd. Hair growth stimulant compositions and method for their stabilization by inhibition of precipitation of crystals

Patent Citations (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US515836A (en) * 1894-03-06 Basin-clamp
US4139619A (en) * 1976-05-24 1979-02-13 The Upjohn Company 6-Amino-4-(substituted amino)-1,2-dihydro-1-hydroxy-2-iminopyrimidine, topical compositions and process for hair growth
US4596812A (en) * 1976-05-24 1986-06-24 The Upjohn Company Methods and solutions for treating male pattern alopecia
US4272516A (en) * 1976-11-08 1981-06-09 Societa Italo-Britannica-L. Manetti-H. Roberts Co. Process for improving transcutaneous and transfollicular absorption of cosmetic compositions
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US4981678A (en) * 1983-10-24 1991-01-01 Soltec Research Pty., Ltd. Foamable biocide composition
US5041439A (en) * 1986-06-13 1991-08-20 The Procter & Gamble Company Penetrating topical pharmaceutical compositions
US4820512A (en) * 1986-08-07 1989-04-11 L'oreal Composition in the form of a gel for inducing and stimulating hair growth and for decreasing their loss, based on piperidinopyrimidine derivatives
US5643942A (en) * 1986-08-08 1997-07-01 The Upjohn Company Methods, composition and solutions for treating alopecia
US5571841A (en) * 1986-12-23 1996-11-05 Tristrata Technology, Inc. Method of treating wrinkles using mandelic acid
US4882182A (en) * 1987-01-08 1989-11-21 Soltec Research Pty. Ltd. Aerosol product
US4828837A (en) * 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5030442A (en) * 1987-03-30 1991-07-09 Liposome Technology, Inc. Non-crystalline minoxidil composition
US5156836A (en) * 1987-10-02 1992-10-20 Shiseido Company Ltd. Hair revitalizing tonic composition
US4866067A (en) * 1987-12-07 1989-09-12 Ricerche De Schiena s.n.c del Dr. Michele Giuseppe Di Schiena & C. 6-piperidino-2,4-diaminopyrimidine-3-oxide salt of 3-carboxypyridine n-oxide and topical, related compositions
US4888354A (en) * 1987-12-21 1989-12-19 Theratech, Inc. Skin penetration enhancement using free base and acid addition salt combinations of active agents
US5225189A (en) * 1988-02-18 1993-07-06 The Upjohn Company Minoxidil gel
US5006332A (en) * 1988-06-17 1991-04-09 L'oreal Composition for inducing and stimulating the growth of hair and/or retarding its loss, based on an amphoteric surface-active agent and on a pyrimidine derivative
US4938953A (en) * 1988-08-09 1990-07-03 The Upjohn Company Self-preserving conditioning shampoo formulation
US5104646A (en) * 1989-08-07 1992-04-14 The Procter & Gamble Company Vehicle systems for use in cosmetic compositions
US5578599A (en) * 1990-08-10 1996-11-26 The Upjohn Company Stimulation of hair growth with minoxidil and a 5α-reductase inhibitor
US5516504A (en) * 1990-09-03 1996-05-14 Soltec Research Pty. Ltd. Concentrated water-free aerosol space spray
US5935554A (en) * 1990-09-03 1999-08-10 Soltec Research Pty. Ltd. Concentrated aerosol space spray that is not an emulsion
US5753216A (en) * 1991-03-19 1998-05-19 The Procter & Gamble Company Hair care compositions having styling/conditioning agent and plasticizer
US5783202A (en) * 1995-03-14 1998-07-21 Soltec Research Pty. Ltd. Pediculicidal mousse composition for killing head lice
US5834014A (en) * 1995-10-06 1998-11-10 The Regents Of The University Of Michigan Stimulation of hair follicles
US5788155A (en) * 1996-06-28 1998-08-04 S. C. Johnson & Son, Inc. Air freshener dispenser device with dual cartridge capacity
US6211250B1 (en) * 1996-11-22 2001-04-03 Soltec Research Pty Ltd. Percutaneous delivery system
US6255313B1 (en) * 1997-01-23 2001-07-03 Taisho Pharmaceutical Co., Ltd. Sustained release hair growth composition
US6267949B1 (en) * 1997-05-20 2001-07-31 Soltec Research Pty Ltd. Sunscreen composition
US6231875B1 (en) * 1998-03-31 2001-05-15 Johnson & Johnson Consumer Companies, Inc. Acidified composition for topical treatment of nail and skin conditions
US6946120B2 (en) * 1998-04-22 2005-09-20 Connetics Australia Pty. Ltd. Pharmaceutical composition
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6419913B1 (en) * 1998-08-04 2002-07-16 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
US20030157046A1 (en) * 2000-04-07 2003-08-21 Koji Imamura Minoxidil-containing preparations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008078905A1 (en) * 2006-12-22 2008-07-03 Cj Cheiljedang Corporation Compositions for external use containing minoxidil for hair growth which have an improved skin permeability
KR100893469B1 (en) * 2006-12-22 2009-04-17 씨제이제일제당 (주) Compositions containing minoxidil for the hair generation which have an improved skin permeation
US20090016970A1 (en) * 2007-02-22 2009-01-15 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US8021649B2 (en) * 2007-02-22 2011-09-20 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
US8231863B2 (en) 2007-02-22 2012-07-31 Cronk Peter J Continuous spray scalp therapy and dispensing systems for same
WO2014184173A1 (en) * 2013-05-14 2014-11-20 Montero Gida Sanayi Ve Ticaret A.S. Hair care formulations

Also Published As

Publication number Publication date
US20020172649A1 (en) 2002-11-21
JP2004059587A (en) 2004-02-26
EP1695708B1 (en) 2018-02-28
EP1695708A2 (en) 2006-08-30
CA2328950C (en) 2008-07-29
US6946120B2 (en) 2005-09-20
WO1999053923A1 (en) 1999-10-28
ES2268856T3 (en) 2007-03-16
AUPP310798A0 (en) 1998-05-14
CA2328950A1 (en) 1999-10-28
PT1073439E (en) 2006-11-30
JP2002512192A (en) 2002-04-23
JP4338455B2 (en) 2009-10-07
PT1695708T (en) 2018-05-18
JP3710380B2 (en) 2005-10-26
CY1120513T1 (en) 2019-07-10
EP1073439A1 (en) 2001-02-07
EP1073439A4 (en) 2003-07-02
ATE331517T1 (en) 2006-07-15
DE69932158T2 (en) 2007-05-10
EP1695708A3 (en) 2012-07-18
DK1695708T3 (en) 2018-04-23
ES2665271T3 (en) 2018-04-25
EP1073439B1 (en) 2006-06-28
DE69932158D1 (en) 2006-08-10
BR9909796B1 (en) 2013-10-29
BR9909796A (en) 2000-12-26
JP2007137899A (en) 2007-06-07
DK1073439T3 (en) 2006-10-23

Similar Documents

Publication Publication Date Title
US6946120B2 (en) Pharmaceutical composition
AU597734B2 (en) Sebum-dissolving nonaqueous minoxidil formulation
WO1988001863A1 (en) Foams for delivery of minoxidil
CA2170016C (en) Improved method for treating hair loss
US20030049336A1 (en) Composition and method for topical treatment of androgenic alopecia
US20040184992A1 (en) Mousse composition
US20190175491A1 (en) Topical compositions of apremilast
KR20070020139A (en) Formulation for stimulating hair growth
PT1024792E (en) Topical antifungal composition
IE913469A1 (en) Novel composition
JPH08277209A (en) Revitalizing hair tonic
JP4940527B2 (en) Sustainable hair growth composition
JPH0262818A (en) Hair-tonic composition
EP0440811B1 (en) Composition for percutaneous administration
AU757601B2 (en) Pharmaceutical composition
CN116600786A (en) Topical formulations containing JAK inhibitors and laureth-4
JPWO2003030844A1 (en) Sustainable hair growth preparation
JPH04108722A (en) Trichogenous agent
JP2600794B2 (en) Hair growth agent
JP4892786B2 (en) Sustainable hair growth preparation
JPH04120011A (en) Hair growing agent
JPH04159207A (en) Hair-producing agent

Legal Events

Date Code Title Description
AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERA

Free format text: FIRST LIEN PATENT SECURITY AGREEMENT;ASSIGNORS:STIEFEL LABORATORIES, INC.;CONNETICS CORPORATION;REEL/FRAME:018806/0699

Effective date: 20061228

AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERA

Free format text: SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNORS:STIEFEL LABORATORIES, INC.;CONNETICS CORPORATION;REEL/FRAME:018816/0602

Effective date: 20061228

AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERA

Free format text: FIRST LIEN PATENT SECURITY AGREEMENT;ASSIGNORS:STIEFEL LABORATORIES, INC.;CONNETICS CORPORATION;REEL/FRAME:018951/0380

Effective date: 20061228

AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS COLLATERA

Free format text: SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNORS:STIEFEL LABORATORIES, INC.;CONNETICS CORPORATION;REEL/FRAME:018961/0012

Effective date: 20061228

AS Assignment

Owner name: STIEFEL RESEARCH AUSTRALIA PTY LTD, AUSTRALIA

Free format text: CHANGE OF NAME;ASSIGNOR:CONNETICS AUSTRALIA PTY LTD;REEL/FRAME:019448/0259

Effective date: 20070326

AS Assignment

Owner name: STIEFEL LABORATORIES, INC., FLORIDA

Free format text: RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNOR:DEUTSCHE BANK TRUST COMPANY AMERICAS;REEL/FRAME:021439/0259

Effective date: 20080820

Owner name: CONNETICS CORPORATION, CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNOR:DEUTSCHE BANK TRUST COMPANY AMERICAS;REEL/FRAME:021439/0259

Effective date: 20080820

Owner name: STIEFEL LABORATORIES, INC., FLORIDA

Free format text: RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNOR:DEUTSCHE BANK TRUST COMPANY AMERICAS;REEL/FRAME:021439/0201

Effective date: 20080820

Owner name: CONNETICS CORPORATION, CALIFORNIA

Free format text: RELEASE OF SECURITY INTEREST IN CONNECTION WITH SECOND LIEN PATENT SECURITY AGREEMENT;ASSIGNOR:DEUTSCHE BANK TRUST COMPANY AMERICAS;REEL/FRAME:021439/0201

Effective date: 20080820

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION